Wednesday, 8 April 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 08 April 2026
News

After 1192 days, is funding in sight?

Posted 7 April 2026 AM

A drawn-out HTA negotiation process that has already lasted 1192 working days is coming to an end, with the Federal Government teasing that another CAR T-cell therapy will soon be subsidised.

Johnson & Johnson Innovative Medicine's multiple myeloma therapy Carvykti is closing in on reimbursement with Minister for Health and Ageing Mark Butler revealing during question time that the Department and the States are close to reaching an agreement.

To see the whole article, please login

Popular

Global pharma inks Arrotex deal
Seven novel drugs hit the PBS
Aussie pharma exec wins CEO job
And again... MA fills media role
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (14)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Other (8)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home